TY - JOUR T1 - Active growth signalling promotes cancer cell sensitivity to the CDK7 inhibitor ICEC0942 JF - bioRxiv DO - 10.1101/2021.09.10.459733 SP - 2021.09.10.459733 AU - G.A. Wilson AU - G. Sava AU - K. Vuina AU - C. Huard AU - L. Meneguello AU - J. Coulombe-Huntington AU - T. Bertomeu AU - R.J. Maizels AU - J. Lauring AU - M. Tyers AU - S. Ali AU - C. Bertoli AU - R.A.M. de Bruin Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/09/10/2021.09.10.459733.abstract N2 - CDK7 has a central role in promoting cellular proliferation, through the activation of the mitotic CDKs, and by driving global gene expression, through targeting RNA polymerase II. Several recently developed CDK7 inhibitors (CDK7i) have been shown to be non-toxic and to limit tumour growth for a number of cancer cell types and are now in Phase I/II clinical trials. However, the mechanisms underlying the sensitivity of particular cancer cells to CDK7 inhibition remain largely unknown.To improve the outcome of individual patients and increase the chances of successful CDK7i approval, we assessed which fundamental cellular processes determine sensitivity to CDK7 inhibition, using the highly specific CDK7 inhibitor ICEC0942. Our data shows that selective CDK7 inhibition acutely arrests cells in the G1 phase of the cell cycle, which over time leads to senescence. Through a genome-wide CRISPR knock-out chemogenetic screen we identified active mTOR (mammalian target of rapamycin) signalling, as an important determinant of ICEC0942-induced senescence and show that a cancer-associated mutation that promotes cell growth can increase sensitivity to ICEC0942. Our work indicates that cellular growth is an important predictive marker for sensitivity to CDK7i.Competing Interest StatementThe authors have declared no competing interest. ER -